Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on October 4, 2021. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol OGEN. The report discloses a specific event occurring on the filing date regarding a new research grant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a grant award of $250,000.
Material Changes
On October 4, 2021, the Company was awarded a Small Business Innovation Research (SBIR) grant totaling $250,000. This funding is designated for the continued research and development of lantibiotics, specifically supporting a collaborative program with the Biomolecular Sciences Institute at Florida International University.
Outlook, Risks, and Management Commentary
Management highlighted the grant as a milestone for its lantibiotics research pipeline. The filing does not contain updated financial guidance, specific risk factors, or discussion of contingencies beyond the announcement of the grant. The report was signed by Michael Sullivan, Interim Principal Executive Officer and Chief Financial Officer.
Investor Verification Checklist
- Verify the terms and milestones associated with the $250,000 SBIR grant.
- Review the attached Press Release (Exhibit 99.1) for details on the collaboration with Florida International University.
- Check subsequent filings for the impact of this grant on the company's cash position and R&D timeline.
- Confirm the status of the company's interim leadership team.